Literature DB >> 30447013

Integrating anatomo-physiological changes and pharmacogenomics in anti-infective therapy management: is it a major concern?

Laura Beaumier1, Sébastien Chanoine1,2, Elodie Gautier-Veyret2,3,4, Hélène Pluchart1, Muriel Cornet2,5,6, Marie-Pierre Brenier-Pinchart6,7, Xavier Fonrose3, Boubou Camara8, Pierrick Bedouch1,2,9.   

Abstract

Success of anti-infective therapy is a major challenge in some patients given anatomo-physiological changes and genetic variations. In this case anecdote, we report the management strategy of a patient suffering from chronic pulmonary aspergillosis in a context of anorexia nervosa and genetic polymorphism.
© 2018 The British Pharmacological Society.

Entities:  

Keywords:  cytochrome P450 enzymes; drug metabolism; genetic polymorphism; pharmacogenomics; therapeutic drug monitoring

Mesh：

Substances：

Year:  2018        PMID： 30447013      PMCID： PMC6303195          DOI： 10.1111/bcp.13785

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  12 in total

Review 1.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

2.  Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach.

Authors:  Michel Tod; Christina Nkoud-Mongo; François Gueyffier
Journal:  AAPS J       Date:  2013-09-12       Impact factor: 4.009

3.  Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.

Authors:  Brad Moriyama; Sameer Kadri; Stacey A Henning; Robert L Danner; Thomas J Walsh; Scott R Penzak
Journal:  Curr Fungal Infect Rep       Date:  2015-04-16

4.  Pharmacogenetics may influence the impact of inflammation on voriconazole trough concentrations.

Authors:  Elodie Gautier-Veyret; Sebastien Bailly; Xavier Fonrose; Julia Tonini; Simon Chevalier; Anne Thiebaut-Bertrand; Françoise Stanke-Labesque
Journal:  Pharmacogenomics       Date:  2017-07-26       Impact factor: 2.533

5.  Response to "Impact of CYP3A4 Genotype on Voriconazole Exposure: New Insights Into the Contribution of CYP3A4*22 to Metabolism of Voriconazole".

Authors:  Thomas J Walsh; Brad Moriyama; Scott R Penzak; Teri E Klein; Kelly E Caudle
Journal:  Clin Pharmacol Ther       Date:  2017-11-16       Impact factor: 6.875

6.  Simultaneous quantitation of azole antifungals, antibiotics, imatinib, and raltegravir in human plasma by two-dimensional high-performance liquid chromatography-tandem mass spectrometry.

Authors:  Jean-François Jourdil; Julia Tonini; Françoise Stanke-Labesque
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-01-09       Impact factor: 3.205

7.  Diamine oxidase activity levels in anorexia nervosa.

Authors:  Yoshiyuki Takimoto; Kazuhiro Yoshiuchi; Satoshi Shimodaira; Akira Akabayashi
Journal:  Int J Eat Disord       Date:  2013-10-30       Impact factor: 4.861

8.  Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.

Authors:  Ina Scholz; Heike Oberwittler; Klaus-Dieter Riedel; Jürgen Burhenne; Johanna Weiss; Walter E Haefeli; Gerd Mikus
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

9.  In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates.

Authors:  Sylvain Goutelle; Laurent Bourguignon; Nathalie Bleyzac; Johanna Berry; Fannie Clavel-Grabit; Michel Tod
Journal:  AAPS J       Date:  2013-01-15       Impact factor: 4.009

10.  Intestinal permeability is decreased in anorexia nervosa.

Authors:  P Monteleone; R Carratù; M Cartenì; M Generoso; M Lamberti; L De Magistris; F Brambilla; B Colurcio; M Secondulfo; M Maj
Journal:  Mol Psychiatry       Date:  2004-01       Impact factor: 15.992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.